Company: SMNR
Filing Date: 2025-04-21
Form Type: S-4/A
Source: 0001193125-25-087342
Chunk: 81

Company: Semnur Pharmaceuticals, Inc.
Filing Date: 2025-04-21
Form: S-4/A
Chunk 81
---
 soliciting proxies for the Meeting. Denali has engaged Advantage Proxy, Inc. to assist in the solicitation of proxies for the Meeting. Denali has agreed to pay Advantage Proxy, Inc. a fee of $       , plus disbursements (to be paid with non-Trust Account funds). Denali will also reimburse banks, brokers and other custodians, nominees and fiduciaries representing beneficial owners of Denali Ordinary Shares for their expenses in forwarding soliciting materials to beneficial owners of Denali Ordinary Shares and in obtaining voting instructions from those owners. Denali’s directors and officers may also solicit proxies by telephone, by facsimile, by mail, on the Internet or in person. They will not be paid any additional amounts for soliciting proxies. |

| Q: | What happens if I sell my shares before the Meeting? |

| A: | The Record Date for the Meeting is earlier than the date of the Meeting, as well as the date that the Business Combination is expected to be consummated. If you transfer your Denali Class A Ordinary Shares after the Record Date, but before the Meeting, unless the transferee obtains from you a proxy to vote those shares, you would retain your right to vote at the Meeting, but will transfer ownership of the shares and will not hold an interest in Denali after the Business Combination is consummated. |

| Q: | Are Semnur’s stockholders required to approve the Business Combination? |

| A: | Yes. The Semnur stockholders are required to approve the Business Combination. |

Scilex entered into the Company Stockholder Support Agreement with Denali and Semnur, pursuant to which Scilex agreed to vote all Semnur Common Stock beneficially owned by it, including any additional shares of Semnur it acquires ownership of or the power to vote, in favor of the Business Combination and related transactions. As of the date of this proxy statement/prospectus, Scilex owns all of the issued and outstanding shares of Semnur Common Stock.

| Q: | Are there risks associated with the Business Combination that I should consider in deciding how to vote? |

| A: | Yes. There are a number of risks related to the Business Combination and other transactions contemplated by the Merger Agreement that are discussed in this proxy statement/prospectus. Please read with particular care the detailed description of the risks described in “Risk Factors” beginning on page 69 of